We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Immupharma Plc | LSE:IMM | London | Ordinary Share | GB0033711010 | ORD 1P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.02 | -0.93% | 2.14 | 2.10 | 2.18 | 2.19 | 2.11 | 2.11 | 1,367,460 | 16:35:10 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Finance Services | 0 | -3.81M | -0.0114 | -1.92 | 7.3M |
From Apr 2022 to Apr 2024
By Elena Vardon
Shares in ImmuPharma PLC rose 24% on Monday after the group and its partner Avion Pharmaceuticals confirmed that a Phase 2/3 adaptive trial will be the best design for its Lupuzor lupus treatment's next clinical study.
At 0823 GMT, shares were up 0.63 pence at 3.25 pence.
The pharmaceutical company said the study is expected to start in the second half of 2023 after submission through the Food and Drug Administration and Prescription Drug User Fee Act process.
It said the study is expected to be cheaper and the overall timelines faster as the need to stop and start two independent trials, regulatory checks, ethics approvals and site setups are avoided.
Write to Elena Vardon at elena.vardon@wsj.com
(END) Dow Jones Newswires
February 06, 2023 03:43 ET (08:43 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Immupharma Chart |
1 Month Immupharma Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
